CAMBRIDGE, MA: The Novartis Institutes for BioMedical Research (NIBR), the Swiss drug giant's global research organization, has named Feinstein Kean Healthcare (FKH) its first-ever agency of record.
Marcia Kean, CEO of FKH, said it's the shared expertise of the agency and institute in both pharmaceuticals and biotechnology that made them both a good fit.
"We are very much at that intersection between big pharma and biotech. NIBR is at that same intersection," said Kean.
NIBR, which was created to help advance ...